$55M invested into MND research since 2014

FightMND is Australia’s largest independent funder of MND research.

We work closely with other relevant MND bodies, taking a lead role in new drug development and clinical trials and doing so with a sense of urgency on behalf of all Australian’s currently fighting MND.

Thanks to our supporters, we have invested more than $55.9 million into research projects and initiatives since we began in 2014.

2022 Research Grants are now open

Applications are now open for the FightMND 2022 Research Grant round are now open. Funding is available for clinical trials, drug development and IMPACT projects.

In December 2021, additional funding opportunities will be announced as part of a three-year program focused on capacity building, innovation and collaboration within MND research.

FightMND invests a further $10.7M in the fight against MND

The fight against Motor Neurone Disease (MND) has received a multi-million-dollar boost with FightMND announcing a further $10.7 million investment into research and care equipment for people living with MND.

This major funding commitment takes the total amount the charity has invested into research and care to more than $63 million since it began in 2014.

Of the total $10.7 million investment in 2021, $8.4 million will go towards 16 MND research projects including one clinical trial, five drug development projects and ten IMPACT projects to help accelerate the development of promising research and effective therapies for MND.

Announced at the Big Freeze 7 in Melbourne this year, the Federal Government also pledged an additional $2 million towards an exciting new MND research initiative, which will be finalised in the coming months.

For the full project summaries, click here.

For more information about the announcement, click here. 


Phase 1b – Ephrin receptor A4-Fc (new drug)

Prof Perry Bartlett, AO
The University of Queensland


Drug Development projects are focused on advancing promising new drugs or therapies through the final stages of testing in preparation for their assessment in clinical trials with MND patients. In 2021, FightMND awarded 5 Drug Development projects.

1. Preventing neuroinflammation in MND by inhibiting the mPTP

A/Prof Seth Masters

2. Alpha 5 Beta 1 Integrin as a potential treatment for MND

Prof Lawrence Steinman
(Alpha 5 Integrin LLC, CA, USA)

3. Developing a monoclonal antibody modulating CD38 against MND

Dr Damien Toulorge
(ENCEFA, France)

4. Targeting misfolded proteins with misfoldUbLs as a therapeutic strategy for MND

Prof Justin Yerbury
(University of Wollongong, NSW)

5. Targeting CK1e-mediated TDP-43 Phosphorylation in MND

Dr John Ravits
(University of California – San Diego, CA, USA)


To accelerate the development of effective therapies for MND, FightMND IMProving and ACcelerating Translation (IMPACT) grants support projects focused on overcoming one or more key barriers preventing the advancement of potential treatments through to clinical trial. In 2021, FightMND awarded 10 IMPACT grants to support projects dedicated to accelerating promising research discoveries through to the clinic.

1. Disease biomarkers – Generating a proteomics-based biomarker for MND

Dr Allan McRae
(University of Queensland, QLD)

2. Disease biomarkers – EC-FUS – A novel biomarker for MND examined using a unique antibody

Prof Julie Atkin
(Macquarie University, NSW)

3. Disease biomarkers – The Glymphatic System: A novel biomarker of disease severity in MND

A/Prof David Wright
(Monash University, VIC)

4. Disease heterogeneity – Exploiting cryptic relatedness in global MND to uncover disease- and phenotype-linked genes

Dr Kelly Williams
(Macquarie University, NSW)

5. Disease heterogeneity – Developing a high-throughput system to identify MND risk genes

Dr Fleur Garton
(University of Queensland, QLD)

6. Disease heterogeneity – Identifying novel structural variations in MND genes to improve clinical trial outcomes

Prof P. Anthony Akkari
(Perron Institute for Neurological and Translational Science, WA)

7. Gene therapies – Restoring autoregulation of TDP43 in MND using splice-switching antisense oligonucleotides

A/Prof Lezanne Ooi
(University of Wollongong, NSW)

8. Drug delivery/Gene therapies – Enhancing delivery of gene therapy to motor neurons and glial cells using focused ultrasound

Dr Kara Vine
(University of Wollongong, NSW)

9. Regenerative medicine – Subpial spinal cord delivery as a stem cell-based treatment for MND

A/Prof Lachlan Thompson
(University of Melbourne, Florey, VIC)

10. Disease models – Harnessing phase separation as a preclinical strategy for the treatment of MND

Dr Marco Morsch
(Macquarie University, NSW)

Join the fight,
donate today

Donate Now